ARS Pharmaceuticalsの空売り状況は、投資家がARS Pharmaceuticalsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

ARS Pharmaceuticals (NASDAQ:SPRY) 株価情報, 空売り情報

ARS Pharmaceuticals

ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.

ARS Pharmaceuticals Inc

Waterdrop (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WDH#NYSE">WDH</a>) reported quarterly sales of $94.09 million which beat the analyst consensus estimate of $93.89 million by 0.21 percent. This is a 1.32 percent increase over sales of $92.87 million the same period last year.

Earnings

Earnings Beats

News

Waterdrop Q4 Sales $94.09M Beat $93.89M Estimate

Mizuho analyst Sean Kennedy initiates coverage on Moodys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCO#NYSE">MCO</a>) with a Neutral rating and announces Price Target of $504.

Price Target

Initiation

Analyst Ratings

Mizuho Initiates Coverage On Moodys with Neutral Rating, Announces Price Target of $504

Anatoly Dritschilo, Chairman of the Company's Board of Directors, will continue in his role as Co-CEO overseeing the Company's scientific and clinical trial activities.

Management

SHPH

Shuttle Pharmaceuticals Appoints Christopher Cooper As Interim Co-CEO

Contracts

NIPG

NIP Group Officially Renewed Their Partnership With Iconic Energy Drink Brand Red Bull

APPN

PEGA

Appian Announced That The Supreme Court Of Virginia Agreed To Hear Its Petition Seeking To Reinstate The $2.036B Judgement Against Pegasystems, Inc.

Mizuho analyst Sean Kennedy initiates coverage on S&amp;P Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPGI#NYSE">SPGI</a>) with a Outperform rating and announces Price Target of $599.

SPGI

Mizuho Initiates Coverage On S&P Global with Outperform Rating, Announces Price Target of $599

The funds will be used to maintain the company's velocity through its fully implanted Acclaim cochlear implant pivotal clinical trial and support other operations.
The $10 million lending facility has a five-year term, is unsecured, does not have a conversion feature, and defers interest for the first two years.&nbsp; &nbsp;

Envoy Medical, Inc. - Class A Common Stock

COCH

Envoy Medical Secures $10M In Financing From Its Largest Existing Shareholder, Billionaire Entrepreneur Glen Taylor

Guidance

BURU

Nuburu On Tuesday Said Believes That The Intellectual Property, Key Personnel, Relationships It Retains Will Be Sufficient To Allow It To Continue To Develop And Operate Within The Laser Technology Field, Focused Attention On Applications In Defense, Semiconductor, Industrial Manufacturing Sectors

Centene Expects To Reaffirm Its Previously Issued 2025 Adjusted EPS Guidance Of Greater Than $7.25 (Est $7.23) - Filing

Target Announced The Return Of Target Circle Week March 23-29, Delivering Seven Days Of Exclusive Deals And Up To 40% Off For Members Of The Retailer's Free-to-join Target Circle Program

Nokia Announced That Canal+ Telecom, Will Deploy Its Lightspan And Altiplano Solution To Support The Transformation Of Its Fiber Network Across French Guiana And Guadeloupe

Buybacks

IBTA

Ibotta Plans $100M Increase To Its Share Repurchase Program

National Energy Services (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NESR#NASDAQ">NESR</a>) reported quarterly earnings of $0.30 per share which beat the analyst consensus estimate of $0.27 by 11.11 percent. The company reported quarterly sales of $343.68 million which missed the analyst consensus estimate of $347.90 million by 1.21 percent.

Earnings Misses

NESR

National Energy Services Q4 2025 Adj EPS $0.30 Beats $0.27 Estimate, Sales $343.68M Miss $347.90M Estimate

CLEAR Continues To Expand Locations Outside The Airport Environment To Enroll And Renew Consumers In The Trusted Traveler Program By Opening New Locations At Sawgrass Mills, The Florida Mall, The Galleria, And Lenox Square

On Tuesday, Rocket Lab USA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) inked a non-binding term sheet with certain lenders to acquire a <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44264701/rocket-lab-announces-intention-to-acquire-mynaric-leading-laser-communications-provider-in-latest-" rel="noreferrer noopener">controlling stake in </a><a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44264701/rocket-lab-announces-intention-to-acquire-mynaric-leading-laser-communications-provider-in-latest-" rel="noreferrer noopener">Mynaric AG</a>.
Upon execution of a definitive agreement, Rocket Lab would acquire 100% of Mynaric for an initial $75 million, payable in cash or Rocket Lab stock. An additional earn-out of up to $75 million, also in cash or stock, is tied to future revenue targets.
The initial purchase price may increase if the Lenders or affiliates invest more cash in Mynaric post-restructuring, with a corresponding reduction in earn-out potential.
The acquisition is subject to regulatory approvals and the completion of Mynaric&#8217;s ongoing StaRUG restructuring under German law. The transaction is expected to close upon fulfillment of these conditions.
The non-binding term sheet grants Rocket Lab an exclusive negotiation period with the Lenders, subject to due diligence and the execution of a definitive purchase agreement.
Rocket Lab&#8217;s proposed acquisition of Mynaric is driven by their existing partnership, with Mynaric supplying CONDOR Mk3 optical communication terminals for Rocket Lab's $515 million SDA contract to produce 18 satellites.
Rocket Lab aims to scale production and enhance manufacturing efficiencies to ensure timely, cost-effective terminal deliveries for SDA and other clients.
Read: <a target="_blank" href="https://www.benzinga.com/general/space/25/02/44034215/rocket-lab-unveils-flatellite-low-cost-mass-producible-satellite-to-target-large-constellations-amid-weak-q1-guidance" rel="noreferrer noopener">Rocket Lab Unveils &#8216;Flatellite:&#8217; Low-Cost, Mass-Producible Satellite To Target Large Constellations Amid Weak Q1 Guidance</a>
Rocket Lab founder and CEO Sir Peter Beck said, &#8221;Mynaric has paved the way in developing laser technology. Their team and technologies will make a compelling addition to our satellite component portfolio and we look forward to making the technology available at scale for our own constellations and those of our customers.&#8221;
In a separate release, Rocket Lab&nbsp;filed a prospectus supplement with the SEC for an &#8220;at the market&#8221; (ATM) offering of up to <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44264676/rocket-lab-announces-at-the-market-atm-equity-offering-program" rel="noreferrer noopener">$500 million in common stock</a>.
The company currently intends to use the net proceeds to fund future growth, including potential acquisitions such as Mynaric and for general corporate and working capital purposes.
Investors can gain exposure to the stock via ARK Space Exploration &amp; Innovation ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKX#BATS">ARKX</a>) and Tidal ETF Trust II Pinnacle Focused Opportunities ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCUS#NYSE">FCUS</a>)
Price Action: RKLB shares are up 1.01% at $18.00 premarket at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/etfs/sector-etfs/25/03/44253929/space-etfs-rocked-by-intuitive-machines-lunar-mishap-is-there-a-safer-bet" target="_blank" rel="noreferrer noopener">Space ETFs Rocked By Intuitive Machines&#8217; Lunar Mishap — Is There A Safer Bet?</a></li>
</ul>
Image via Shutterstock.

Equities

Large Cap

Movers

ARKX

FCUS

RKLB

Rocket Lab Expands Its Space Arsenal: Eyes Laser Tech Boost With Mynaric Buyout

Brenntag (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BNTGY#OTC">BNTGY</a>) reported quarterly earnings of $0.19 per share. This is a 9.52 percent decrease over earnings of $0.21 per share from the same period last year. The company reported $4.26 billion in sales this quarter. This is a 2.05 percent decrease over sales of $4.35 billion the same period last year.

BNTGY

Brenntag Q4 EPS $0.19 Down From $0.21 YoY, Sales $4.26B Down From $4.35B YoY

Morgan Stanley analyst David Arcaro initiates coverage on Talen Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLN#NASDAQ">TLN</a>) with a Overweight rating and announces Price Target of $243.

Morgan Stanley Initiates Coverage On Talen Energy with Overweight Rating, Announces Price Target of $243

U.S. stock futures were up on Wednesday after a volatile session on Tuesday. Futures of all four benchmark indices advanced in premarket trading.
Investors will keep an eye on pivotal February inflation data as stagflation worries have been weighing on Wall Street. Economists polled by TradingEconomics predict a shift in inflation trends, with annual headline inflation expected to drop to 2.9% in February, breaking four months of increases. Monthly price growth is also forecast to slow, as is core inflation, which excludes volatile food and energy costs.
On Tuesday afternoon, President Donald Trump reversed his decision to double tariffs on Canadian steel and aluminum to 50%, just hours after announcing the hike. The sudden shift, which unsettled financial markets, came after a Canadian official withdrew plans for a 25% surcharge on electricity.
Meanwhile, the 10-year Treasury yield stood at 4.27%, while the two-year yield was at 3.94%. According to the CME Group's FedWatch <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">tool</a>, there is a 97% chance that the Federal Reserve will keep interest rates unchanged for the March meeting. 
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>0.71%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.58%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.41%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>0.63%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, rose in premarket on Wednesday. The SPY was up 0.72% to $559.92, and the QQQ also advanced 0.84% to $475.54, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Cues From The Last Session
The U.S. stock market closed lower on Tuesday after a volatile session. All sectors declined in trade. Industrials, consumer staples, health care and real estate sectors fell over 1%.
On the economic front, small business optimism fell in February, with the NFIB&#8217;s index dropping to 100.7. Uncertainty surged to near-record levels. Additionally, the labor market was strong in January, with rising openings. JOLTS report showed layoffs declining for a fourth straight month to the lowest level since last June.
The S&amp;P 500 index neared correction zone as of Tuesday&#8217;s close, it was 9.36% lower from the previous high of 6,147.43 to 5,572.07 points. Whereas, Nasdaq 100 was 12.80% lower from its 52-week high.
The Dow Jones closed 478 points or 1.14% lower at 41,433.48 on Tuesday, down 8.08% from its previous high.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>-0.18%</td>
<td>17,436.10</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.76%</td>
<td>5,572.07 </td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-1.14%</td>
<td>41,433.48 </td>
</tr>
<tr>
<td>Russell 2000</td>
<td>0.22%</td>
<td>2,023.59</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts
Ryan Detrick, the chief market strategist at Carson Research, highlighted in his note &#8216;March Madness,&#8217; that the seasonally the end of February and beginning of March are bound to see weakness.
However, he acknowledged that a correction was at hand, adding, &#8220;We do not expect things to get much worse and the odds of a full-blown bear market remain quite slim. As uncomfortable as this recent volatility feels, know that it is the toll we must pay to invest.&#8221;
According to Ed Yardeni from Yardeni Research, investors were worried about the adverse macroeconomic consequences of all this geopolitical turmoil. &#8220;The uncertainty associated with rapid-fire tariff announcements from the White House could weigh on the economy,&#8221; he said.
As Trump&#8217;s tariffs on steel and aluminum imports take effect, the European Union announced on Wednesday that it would retaliate with levies of 26 billion euros or $28.33 billion on the U.S. goods starting in April in response to the duties.
Highlighting this, economist Mohamed El-Erian hinted at the volatility caused by negotiations between Canada on Tuesday, which will likely translate as a cause of the tensions between the U.S. and EU on Wednesday.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Yesterday&#39;s tariff focus was mainly on the heightened tensions between Canada and US; today, the focus shifts to the EU-US tit-for-tat. (Photo from Bloomberg.)<a href="https://twitter.com/hashtag/economy?src=hash&amp;ref_src=twsrc%5Etfw">#economy</a> <a href="https://twitter.com/hashtag/trade?src=hash&amp;ref_src=twsrc%5Etfw">#trade</a> <a href="https://twitter.com/hashtag/tariffs?src=hash&amp;ref_src=twsrc%5Etfw">#tariffs</a> <a href="https://t.co/KeaknzVr5S">pic.twitter.com/KeaknzVr5S</a>
&mdash; Mohamed A. El-Erian (@elerianm) <a href="https://twitter.com/elerianm/status/1899722713075212796?ref_src=twsrc%5Etfw">March 12, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Whereas, CNBC&#8217;s Jim Cramer quipped that if the President spoke softly, a decent inflation print would uplift the market.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">a decent CPI and we could have a good run IF President Trump decides to speak softly and carry a big stick
&mdash; Jim Cramer (@jimcramer) <a href="https://twitter.com/jimcramer/status/1899639615834718551?ref_src=twsrc%5Etfw">March 12, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures">How to Trade Futures </a>
Upcoming Economic Data
Here&#8217;s what investors will keep on Wednesday:
<ul>
<li>February&#8217;s core and headline consumer price index data will be out by 8:30 a.m., ET.</li>
</ul>
<ul>
<li>Monthly U.S. federal budget data for February will be announced at 2:00 p.m., ET.</li>
</ul>
Stocks In Focus:
<ul>
<li>E W Scripps Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSP#NASDAQ">SSP</a>) surged 37.76% in premarket on Wednesday after it refinanced over $1.3 billion in term loans, secured a new $450 million accounts receivable facility, and a $208 million revolving credit line due 2027.</li>
</ul>
<ul>
<li>Innventure Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INV#NASDAQ">INV</a>) zoomed 32.62% secured a three-year white-label agreement with a major thermal management company and launched a new 250kW multi-rack liquid cooling system.</li>
</ul>
<ul>
<li>Stitch Fix Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFIX#NASDAQ">SFIX</a>) jumped 18.68% after reporting the fourth quarter revenue of $312.1 million, exceeding expectations, with strong next-quarter guidance of $313.5 million.</li>
</ul>
<ul>
<li>StandardAero Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SARO#NYSE">SARO</a>) dropped 15.87% after reporting a $0.04 loss per share, missing estimates by $0.20, but beat revenue expectations with $1.41 billion, up 21.8% year-on-year.</li>
</ul>
<ul>
<li>Starbox Group Holdings Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STBX#NASDAQ">STBX</a>) plunged 19.45% after receiving a Nasdaq non-compliance notice for failing to maintain a $1.00 minimum bid price, with trading suspension set for March 18, 2025.</li>
</ul>
<ul>
<li>Smith Micro Software Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMSI#NASDAQ">SMSI</a>) slumped 17.05% after reporting a $0.11 per share adjusted loss. This follows a previous quarter where their $0.30 loss beat estimates by 3.23%.</li>
</ul>
Commodities, Gold And Global Equity Markets:
Crude oil futures were trading higher in the early New York session by 0.68% to hover around $66.70 per barrel.
The gold spot index was up by 0.15% to $2,920.02 per ounce. Its last record high was at $2,956.37 per ounce. The Dollar Index was up 0.07% at the 103.487 level.
Asian markets closed mostly lower on Tuesday except Japan's Nikkei 225, and South Korea's Kospi index. Australia's ASX 200, Hong Kong's Hang Seng, India's S&amp;P BSE Sensex, and China's CSI 300 index declined. European markets were mostly higher in trade.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44269729/debt-over-equity-billionaire-howard-marks-endorses-credit-investments-amid-shifting-investor-focus-and-market-cor">Billionaire Howard Marks Prefers Credit Over Equity Amid Falling Market: &#8216;Yields Implies Higher Returns From Credit Than The S&amp;P 500&#8217;</a></li>
</ul>
Photo courtesy: Shutterstock

Government

Market Summary

Futures

Treasuries

Economics

Pre-Market Outlook

Markets

SARO

SFIX

SMSI

STBX

US Stocks Likely To Open Higher Ahead Of February's Inflation Print: Expert Says Odds Of A Full-Blown Bear Market Remain 'Quite Slim'

iRobot Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRBT#NASDAQ">IRBT</a>) &nbsp;announced the availability of a suite of new technologically-innovative Roomba&nbsp;vacuums and 2-in-1 vacuums and mops with advanced features, ranging from debris-compacting systems to extending and retractable dual-spinning mop pads that tackle stubborn messes.

Tech

IRBT

iRobot On Tuesday, Announced Suite of ROOMBA Floor Cleaning Robots

VNET

VNET Expects 2025 Total Net Revenues Of RMB9.10B - RMB9.30B (Est RMB9.075B), Representing Growth Of 10% - 13% YoY

Health Care

Press Releases

ARS Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

General

ARS Pharmaceuticals Announces neffy® (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies

Legal

ARS Pharmaceuticals Files for Approval of neffy® in Canada and the United Kingdom on Behalf of Licensing Partner ALK-Abelló A/S

ARS Pharmaceuticals Announces Preliminary Fourth Quarter 2024 Financial Results and 2025 Objectives for neffy® (epinephrine nasal spray)

ARS Pharmaceuticals Launches neffyinSchools Program Providing Free Life-Saving Needle-Free Epinephrine For Emergency Use to Eligible K-12 Schools

ARS Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Conference

ARS Pharmaceuticals to Showcase Innovation and Present Data on neffy® (epinephrine nasal spray) at 2025 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting

ARS Pharmaceuticals Announces OptumRx, Cigna Healthcare and Navitus Health Systems Add neffy® (Epinephrine Nasal Spray) to National Formularies, Further Expanding Coverage for Patients

ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2024 Financial Results and Participation at Upcoming Conferences

ARS Pharmaceuticals Announces FDA Approval of neffy® 1 mg (epinephrine nasal spray) for Type I Allergic Reactions, Including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms

Comments

ARS Pharmaceuticals

空売り

ARS Pharmaceuticals (NASDAQ:SPRY) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル